Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2018 | 1 |
2019 | 1 |
2021 | 1 |
2022 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
Mult Scler. 2022 Jan;28(1):111-120. doi: 10.1177/13524585211010294. Epub 2021 May 10.
Mult Scler. 2022.
PMID: 33969750
Free PMC article.
Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.
Cook S, Leist T, Comi G, Montalban X, Giovannoni G, Nolting A, Hicking C, Galazka A, Sylvester E.
Cook S, et al.
Mult Scler Relat Disord. 2019 Apr;29:157-167. doi: 10.1016/j.msard.2018.11.021. Epub 2018 Nov 20.
Mult Scler Relat Disord. 2019.
PMID: 30885374
Free article.
In general there was no increase in the risk of infections including opportunistic infections with cladribine tablets versus placebo, except for herpes zoster. Periods of severe lymphopenia (< 0.5 10(9) cells/L) were associated with an increased frequency of infections, …
In general there was no increase in the risk of infections including opportunistic infections with cladribine tablets versus placebo, except …
Item in Clipboard
Cite
Cite